NASDAQ:BCLI

Brainstorm Cell Therapeutics Stock Earnings Reports

etoro logo Buy BCLI
*Your capital is at risk
$0.680
+0.0800 (+13.33%)
At Close: Nov 17, 2025

Brainstorm Cell Therapeutics Earnings Calls

Sep 30, 2025
-$0.91 (-160.00%)
Release date Nov 14, 2025
EPS estimate -$0.350
EPS actual -$0.91
EPS Surprise -160.00%
Revenue estimate -
Revenue actual -
Jun 30, 2025
-$0.340 (17.07%)
Release date Aug 14, 2025
EPS estimate -$0.410
EPS actual -$0.340
EPS Surprise 17.07%
Revenue estimate -
Revenue actual -
Mar 31, 2025
-$0.450 (53.61%)
Release date May 15, 2025
EPS estimate -$0.97
EPS actual -$0.450
EPS Surprise 53.61%
Revenue estimate -
Revenue actual -
Dec 31, 2024
-$0.510 (-4.08%)
Release date Mar 31, 2025
EPS estimate -$0.490
EPS actual -$0.510
EPS Surprise -4.08%
Revenue estimate -
Revenue actual 849K

Last 4 Quarters for Brainstorm Cell Therapeutics

Below you can see how BCLI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Dec 31, 2024 Missed
Release date Mar 31, 2025
Price on release $1.26
EPS estimate -$0.490
EPS actual -$0.510
EPS surprise -4.08%
Date Price
Mar 25, 2025 $1.44
Mar 26, 2025 $1.40
Mar 27, 2025 $1.35
Mar 28, 2025 $1.19
Mar 31, 2025 $1.26
Apr 01, 2025 $1.19
Apr 02, 2025 $1.21
Apr 03, 2025 $1.23
Apr 04, 2025 $1.15
4 days before -12.50%
4 days after -8.73%
On release day -5.56%
Change in period -20.14%
Mar 31, 2025 Beat
Release date May 15, 2025
Price on release $1.16
EPS estimate -$0.97
EPS actual -$0.450
EPS surprise 53.61%
Date Price
May 09, 2025 $1.18
May 12, 2025 $1.22
May 13, 2025 $1.21
May 14, 2025 $1.14
May 15, 2025 $1.16
May 16, 2025 $1.32
May 19, 2025 $1.36
May 20, 2025 $1.24
May 21, 2025 $1.18
4 days before -1.69%
4 days after 1.72%
On release day 13.79%
Change in period 0%
Jun 30, 2025 Beat
Release date Aug 14, 2025
Price on release $0.600
EPS estimate -$0.410
EPS actual -$0.340
EPS surprise 17.07%
Date Price
Aug 08, 2025 $0.600
Aug 11, 2025 $0.600
Aug 12, 2025 $0.630
Aug 13, 2025 $0.660
Aug 14, 2025 $0.600
Aug 15, 2025 $0.615
Aug 18, 2025 $0.610
Aug 19, 2025 $0.650
Aug 20, 2025 $0.655
4 days before 0.0167%
4 days after 9.17%
On release day 2.50%
Change in period 9.18%
Sep 30, 2025 Missed
Release date Nov 14, 2025
Price on release $0.600
EPS estimate -$0.350
EPS actual -$0.91
EPS surprise -160.00%
Date Price
Nov 10, 2025 $0.650
Nov 11, 2025 $0.680
Nov 12, 2025 $0.640
Nov 13, 2025 $0.630
Nov 14, 2025 $0.600
Nov 17, 2025 $0.680
4 days before -7.69%
4 days after 13.33%
On release day 13.33%
Change in period 4.62%

Brainstorm Cell Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for BCLI?
Brainstorm Cell Therapeutics Inc. (BCLI) has scheduled its earnings report for Mar 30, 2026 before the markets open.

What is the BCLI price-to-earnings (P/E) ratio?
BCLI P/E ratio as of Nov 17, 2025 (TTM) is -0.512.

What is the BCLI EPS forecast?
The forecasted EPS (Earnings Per Share) for Brainstorm Cell Therapeutics Inc. (BCLI) for the first fiscal quarter 2026 is -$0.280.

What are Brainstorm Cell Therapeutics Inc.'s retained earnings?
On its balance sheet, Brainstorm Cell Therapeutics Inc. reported retained earnings of $0 for the latest quarter ending Sep 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative ...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE